Inhibikase Therapeutics

IKT

Market cap $218M

1.80 USD

-0.03

1.64%

At close Updated Mar 20, 4:00 PM EDT

Pre-market

After hours

1.81

+0.01

0.56%

1 day

-1.64%

5 days

-10.89%

1 month

2.27%

3 months

8.43%

6 months

7.14%

Year to date

-7.69%

1 year

-25.62%

5 years

-94.67%

10 years

-96.97%

About: Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Employees: 16

Healthcare Biotechnology